BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
View original at globenewswire.comBioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030 BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candi…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
We believe that this plan will be additive for both, BioNTech and the new company, as it aims to allow each organization to drive meaningful impact for patients
60% confidenceCo-founders see extraordinary opportunities to unlock the next generation of transformative innovations
60% confidenceUgur and Özlem have established an outstanding track record of innovation over their careers
60% confidenceOver the past 18 years, we have built BioNTech from a start-up into a global biopharmaceutical company with a strong and diversified pipeline
60% confidenceBioNTech expects to maximize value for patients and shareholders with new company structure focusing on distinct strategic priorities
60% confidenceToday, the company is well positioned to advance its mission and evolve into a commercial multi-product company
60% confidenceSigning of binding agreements expected by end of H1/2026
60% confidence2026 will be the first year in which the Company expects multiple late-stage data readouts across major cancer types
60% confidenceDuring the COVID-19 pandemic, we expanded beyond oncology to develop the first approved mRNA vaccine, helping to protect people worldwide
60% confidenceOver the past 18 years, BioNTech has been built from a start-up into a global biopharmaceutical company with a strong and diversified pipeline
60% confidenceOver the course of their careers, Ugur and Özlem have established an outstanding track record of innovation
60% confidenceOur vision has always been to translate our science into meaningful advances for patients, and we see extraordinary opportunities to unlock the next generation of transformative innovations
60% confidenceFor us, this is the right time to prepare to hand over the baton
60% confidenceBioNTech is well positioned to advance its mission and evolve into a commercial multi-product company
60% confidenceBioNTech expects to have 15 ongoing Phase 3 clinical trials in oncology by year end
60% confidenceBioNTech expects to maximize value for patients and shareholders alike
60% confidence2026 will be the first year with multiple late-stage data readouts across major cancer types
60% confidenceBioNTech developed the first approved mRNA vaccine during COVID-19 pandemic
60% confidencePlan will be additive for both BioNTech and the new company, allowing each organization to drive meaningful impact for patients
60% confidenceBioNTech is advancing toward becoming a multi-product company by 2030
60% confidenceBioNTech expects to have 15 ongoing Phase 3 clinical trials in oncology by year end 2026
60% confidence
Cited in these Via News reports
- AI-Designed Antibody BD200 Outperforms Standard Treatments in Drug-Resistant Cancers, Marking First Clinical Trial for Machine Learning Platform →
- AI-Designed Cancer Drug BD200 Defeats Resistant Tumors, Outperforms Marketed Antibodies →
- AI-Designed Drug Candidates Show Clinical Progress Across US and Canadian Trials →
- Amgen Merges R&D and AI Leadership as Global Pharma Embeds Generative AI Into Research Strategy →
- Biotech Firms Secure Capital as Gene Therapy Trials Target 5 Million Global Patients with Dry AMD →
- FDA Fast-Tracks Lung Cancer Drug as Biotech Sector Logs $430M in Deals →
- Global ADC Combination Race Peaks in 2026–2027, Compressing Binary Risk Across Three Continents →
- Global Biotech Valuations Rise as $120B Oncology Pipeline Targets 2026-2027 FDA Approvals →
- Vepdegestrant's 5-Month PFS Anchors Cross-Border Oncology Deals as 2026 PDUFA Cluster Reshapes Global Drug Valuations →